2024 IPO

CG Oncology Stock

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Sign up today and learn more about CG Oncology Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About CG Oncology Stock

CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

Funding History

July 2014$13.6M
August 2015$10.0M
March 2019$22.0M
December 2020$47.0M
November 2022$120M
August 2023$105M

Management

Board Member

Brian Liu

Board Member

Simone Song

VP of Finance, Accounting and Administration

Amy Steele

CEO

Alex Yeung

Vice President of Business Development

Bing Kung

Chief Executive Officer

Arthur Kuan

Chief Scientific Officer

Paola Grandi

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo